Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug–drug interactions and …

Y Shitara, Y Sugiyama - Pharmacology & therapeutics, 2006 - Elsevier
3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) are widely
used for the treatment of hypercholesterolemia. Their efficacy in preventing cardiovascular …

[HTML][HTML] Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in …

…, EHK Stelzer, B Stieger, R Stoeber, Y Sugiyama… - Archives of …, 2013 - Springer
This review encompasses the most important advances in liver functions and hepatotoxicity
and analyzes which mechanisms can be studied in vitro. In a complex architecture of nested, …

Impact of drug transporter studies on drug discovery and development

N Mizuno, T Niwa, Y Yotsumoto, Y Sugiyama - Pharmacological reviews, 2003 - ASPET
Drug transporters are expressed in many tissues such as the intestine, liver, kidney, and brain,
and play key roles in drug absorption, distribution, and excretion. The information on the …

Novel cisplatin-incorporated polymeric micelles can eradicate solid tumors in mice

…, H Cabral, M Miyamoto, Y Kato, Y Sugiyama… - Cancer research, 2003 - AACR
Polymeric micelles incorporating cisplatin (CDDP) were prepared through the polymer-metal
complex formation between CDDP and poly(ethylene glycol)-poly(glutamic acid) block …

Polymorphisms of OATP‐C (SLC21A6) and OAT3 (SLC22A8) genes: Consequences for pravastatin pharmacokinetics

…, S Higuchi, K Otsubo, Y Sugiyama - Clinical …, 2003 - Wiley Online Library
Objective: Our objective was to quantitate the contribution of the genetic polymorphisms of the
genes for 2 human organic anion transporters—organic anion transporting polypeptide C (…

Physiologically‐based pharmacokinetic models for evaluating membrane transporter mediated drug–drug interactions: current capabilities, case studies, future …

…, D Mukherjee, V Dixit, Y Sugiyama… - Clinical …, 2020 - Wiley Online Library
Physiologically‐based pharmacokinetic (PBPK) modeling has been extensively used to
quantitatively translate in vitro data and evaluate temporal effects from drug–drug interactions (…

Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data

…, T Ishizaki, CE Green, CA Tyson, Y Sugiyama - Pharmacology & …, 1997 - Elsevier
As a new approach to predicting in vivo drug metabolism in humans, scaling of in vivo
metabolic clearance from in vitro data obtained using human liver microsomes or hepatocytes is …

Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin

…, Y Kato, H Kusuhara, AH Schinkel, Y Sugiyama - … of Pharmacology and …, 2002 - ASPET
Metformin, a biguanide, is widely used as an oral hypoglycemic agent for the treatment of type
2 diabetes mellitus. The purpose of the present study was to investigate the role of organic …

Transporters as a determinant of drug clearance and tissue distribution

Y Shitara, T Horie, Y Sugiyama - European journal of pharmaceutical …, 2006 - Elsevier
Transporters play an important role in the processes of drug absorption, distribution and
excretion. In this review, we have focused on the involvement of transporters in drug excretion in …

Long-circulating poly (ethylene glycol)–poly (d, l-lactide) block copolymer micelles with modulated surface charge

Y Yamamoto, Y Nagasaki, Y Kato, Y Sugiyama… - Journal of controlled …, 2001 - Elsevier
Reactive polymeric micelles consisting of an α-acetal-poly(ethylene glycol)–poly(d,l-lactide)
block copolymer (acetal-PEG–PDLLA) with a narrow size distribution were prepared in this …